Latest News & Features
Refine Search
article
Nicola Dagg of Allen & Overy discusses what is on the horizon for 2017 at both the Court of Appeal and the UK Supreme Court, at the Life Sciences Patents Network Europe 2016, hosted in London by LSIPR. 20 December 2016
article
Life Sciences Patents Network Europe 2016: Video interview with Sven Bostyn, University of Liverpool
“The regulatory system has to be amended,” says Sven Bostyn of the University of Liverpool, when talking about second medical use patents at the Life Sciences Patents Network Europe 2016, hosted by LSIPR in London. 20 December 2016
Americas
Editas Medicine, a US genome-editing company, has taken a licence to intellectual property relating to CRISPR technologies for human therapeutics, amid a continuing CRISPR patent battle. 20 December 2016
Big Pharma
At the Life Sciences Patents Network Europe 2016, a conference hosted in London by LSIPR, Thomas Kolzau of Enin Pharma led a roundtable on mature licensing strategies. 20 December 2016
Americas
Medical device company Maquet Cardiovascular has filed a complaint against Saphena Medical, a company producing a system known as Venapax, for allegedly infringing its patents. 19 December 2016
Americas
A Boston-based hospital, Brigham and Women’s Hospital, has been awarded $10.2 million in royalty payments after it won a patent case against pharmaceutical company Perrigo. 19 December 2016
Americas
Arent Fox has hired Jay Deshmukh as a partner in the firm's New York office, where he will focus on patent litigation and counselling, particularly for the generic pharmaceutical industry. 16 December 2016
Medtech
Roche has terminated its commercialisation and licensing agreement with Pacific Biosciences for the development and supply of diagnostic products. 16 December 2016
article
At the Life Sciences Patents Network Europe 2016, a conference hosted in London last week by LSIPR, Ednaldo Silva of RoyaltyStat discusses IP licensing in the life sciences industry. 16 December 2016
Americas
Idenix Pharmaceuticals, a subsidiary of Merck, has been awarded $2.5 billion in a patent battle against Gilead over Gilead's drugs Sovaldi and Harvoni, treatments for hepatitis C. 16 December 2016